3 results
Approved WMORecruiting
The primary objective of this study is to evaluate in patients suffering from diffuse cutaneous SSc (DcSSc) the effect of 800mg and 1200mg IVA337 daily on the skin compared to placebo. The modified Rodnan Skin Score (MRSS) will be used to determine…
Approved WMOCompleted
Primary: to assess the efficacy of ambrisentan 5mg after treatment period of 16 weeks, in subjects with inoperable CTEPH. Secondary: safety and tolerability.
Approved WMOCompleted
To investigate the safety and tolerability of the test compoundTo study how the test compound is absorbed, broken-down and excreted by the bodyTo study the effect of the test compound on the functioning of the body, particularly the ovaries and sex…